Hemab Therapeutics Raises $347M in Upsized IPO

Hemab Therapeutics Holdings, Inc. has successfully concluded its initial public offering, raising approximately $346.7 million before expenses. The clinical-stage biopharmaceutical firm, focused on revolutionizing treatments for blood coagulation disorders, saw its shares begin trading on the Nasdaq Global Select Market under the ticker symbol “COAG” on May 1, 2026. The offering was significantly upsized, with underwriters fully exercising their option to purchase an additional 2,512,500 shares, demonstrating robust investor demand for novel therapies in the hematology space.

The substantial capital infusion positions Hemab Therapeutics to advance its promising pipeline, which includes sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 for Von Willebrand Disease. These bispecific and monovalent antibody candidates aim to address critical unmet needs for patients suffering from serious bleeding and thrombotic conditions worldwide. The company's strategic focus on developing life-sustaining treatments underscores the growing investment interest in rare disease therapeutics and precision medicine within the biotechnology sector.

The offering was managed by a syndicate of leading financial institutions, with Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI serving as joint book-running managers. Wedbush PacGrow acted as the lead manager. This strong underwriting syndicate facilitated the successful execution of the offering, highlighting the market's confidence in Hemab's scientific platform and commercial potential. The successful IPO marks a significant milestone for the company, enabling it to progress its drug candidates through late-stage clinical development and towards potential commercialization.

This public offering comes at a time when the biotechnology sector, particularly companies developing treatments for hematological disorders, is experiencing heightened investor attention. The global market for hemophilia treatments alone is projected to reach billions of dollars in the coming years, driven by advancements in gene therapy and novel protein replacement strategies. Hemab's approach, focusing on prophylactic treatments and addressing specific coagulation pathway deficiencies, aligns with these market trends and offers a differentiated therapeutic strategy.

The successful completion of this offering, including the full exercise of the underwriters' option, reflects a strong endorsement of Hemab Therapeutics' innovative approach to managing complex blood disorders. The company's dual presence in Cambridge, Massachusetts, and Copenhagen, Denmark, also highlights the increasingly global nature of biotech innovation and investment. The capital raised will be instrumental in funding ongoing clinical trials and expanding the company's research and development capabilities.

Hemab Therapeutics is dedicated to improving the lives of millions affected by bleeding and thrombotic diseases. By developing therapies that offer sustained protection and enhance resilience, the company is carving out a significant niche in the hematology market. The successful IPO provides the financial foundation necessary to pursue this ambitious mission and deliver on its promise of transforming patient care.